Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 8/20 | 0.63 |
| ▸ | GRM2 | Q14416 | 11/20 | 0.37 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4075887 | 0.89 | ALOX5 (0.69) | ALOX5GRM2GRM3 | |
| SCHEMBL4075973 | 0.86 | ALOX5 (0.71) | ALOX5GRM2GRM3 | |
| SCHEMBL4078591 | 0.83 | ALOX5 (0.68) | ALOX5GRM2GRM3 | |
| SCHEMBL4078588 | 0.80 | ALOX5 (0.55) | ALOX5GRM2 | |
| Setileuton SCHEMBL1528740 | 0.78 | ALOX5 (1.00) | ALOX5GRM2GRM3 | |
| Setileuton SCHEMBL13691961 | 0.78 | ALOX5 (1.00) | ALOX5GRM2GRM3 | |
| Setileuton SCHEMBL29371714 | 0.78 | ALOX5 (1.00) | ALOX5GRM2GRM3 | |
| Setileuton SCHEMBL1528741 | 0.78 | ALOX5 (1.00) | ALOX5GRM2GRM3 | |
| SCHEMBL4085404 | 0.78 | ALOX5 (0.79) | ALOX5GRM2GRM3 | |
| SCHEMBL4075997 | 0.76 | ALOX5 (0.57) | ALOX5GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227638-A1 | Novel Pharmaceutical Compounds | BLOUIN MARC | 2009-09-10 | — | — | US | claimed |
| EP-1869031-A1 | THIADIAZOLE SUBSTITUTED COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITOR | Merck Frosst Canada Ltd. (CA) | 2007-12-26 | — | — | EP | claimed |
| US-20070149579-A1 | Novel pharmaceutical compounds | MERCK CANADA INC. (CA) | 2007-06-28 | — | — | US | claimed |
| WO-2006099735-A1 | THIADIAZOLE SUBSTITUTED COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITOR | MERCK FROSST CANADA LTD. (CA) | 2006-09-28 | — | — | WO | claimed |
| US-20090227638-A1 | Novel Pharmaceutical Compounds | BLOUIN MARC | 2009-09-10 | — | — | US | disclosed |
| US-7553973-B2 | Pharmaceutical compounds | MERCK FROSST CANADA LTD. (CA) | 2009-06-30 | — | — | US | disclosed |
| US-20090030048-A1 | Novel pharmaceutical compounds | BLOUIN MARC | 2009-01-29 | — | — | US | disclosed |
| US-20070149579-A1 | Novel pharmaceutical compounds | MERCK CANADA INC. (CA) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030048-A1 | Novel pharmaceutical compounds | LTA4H, LTB4R2, LTC4S | ALOX5 12/4885GRM2 4272/4885GRM3 4007/4885 |
| US-20070149579-A1 | Novel pharmaceutical compounds | LTA4H, LTB4R2, LTC4S | ALOX5 12/4885GRM2 4272/4885GRM3 4007/4885 |
| US-20090227638-A1 | Novel Pharmaceutical Compounds | LTC4S, LTB4R2, LTB4R | ALOX5 10/4885GRM2 2837/4885GRM3 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.